The research progress on the efficacy enhancement of paclitaxel in chemotherapy for colorectal cancer
10.12206/j.issn.1006-0111.202007031
- VernacularTitle:增强紫杉醇对结直肠癌化疗疗效的研究进展
- Author:
Bingchen CHEN
1
;
Enda YU
1
Author Information
1. Department of Colorectal Surgery, Changhai Hospital Affiliated to Naval Medical University, Shanghai 200433, China.
- Keywords:
paclitaxel;
colorectal cancer;
chemotherapy
- From:
Journal of Pharmaceutical Practice
2020;38(6):501-505
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is a malignant tumor with increasing incidence in China. Chemotherapy or neoadjuvant therapy are needed when the patients have deep tumor invasion of distant metastasis due to the hidden clinical manifestations and limited screening methods for the colorectal cancer. With many side effects of the current chemo-medications and the drug resistance, researchers are actively exploring new chemotherapy drugs for colorectal cancer. Paclitaxel is a first-line chemotherapy drug for the treatment of breast cancer, ovarian cancer, pancreatic cancer and other malignant tumors. Colorectal cancer cells are prone to become resistant to paclitaxel and the treatment efficiency was limited. However, new drug delivery systems and the combination drug therapy can enhance the treatment efficiency. This article reviews the effective treatment strategies of paclitaxel for colorectal cancer with the hope for new ideas and more effective chemotherapy.
